Biotime, Inc.

Cryomedical Sciences Inc.

Automated Packaging Systems, Inc.

Harold D Waitz

Hal Sternberg

Paul E Segall

Judith M Segall

Bruce Cohen

Hershey Lerner

Artificial plasma-like solutions and methods for their use are provided. The subject solutions include: electrolytes and an oncotic agent. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.

Physiologically acceptable aqueous solutions and methods for their use

Methods and compositions for use in perfusion applications are provided. In the subject methods, a subject or derivative thereof, e.g. isolated organ or tissue, is infused, perfused and/or transfused with at least two fluid compositions. The first fluid composition is a non-naturally occurring biological buffer free plasma-like solution and the second fluid composition is a fluid blood composition. In a preferred embodiment, an additional volume of the first solution, or a derivative thereof, is administered to the patient following introduction of the fluid blood composition. Also provided are kits and systems for performing the subject methods. The subject methods and compositions find use in variety of perfusion applications, including the treatment of hypothermic surgical applications, cryogenic procedures, and the like.

Methods and compositions for use in perfusion applications

Physiologically acceptable aqueous solutions and methods for their use are provided. The subject solutions comprise: electrolytes; a dynamic buffering system and an oncotic agent; and do not comprise a conventional biological buffer. The subject solutions find use in a variety of applications, particularly in those applications where at least a portion of a host's blood volume is replaced with a blood substitute.

An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, which is buffered by lactate and has a pre-administration pH of between 4 and 6.5 is disclosed. In one embodiment, the artificial plasma-like solution may have at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplementation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. Methods for the administration of the plasma-like solution are also disclosed.

Solutions for use as plasma expanders and substitutes

Method and compositions for use in perfusion applications

Solutions are described which are useful as plasma expanders and blood substitutes in mammals, including primates, and methods for using the solutions.

Plasma expanders and blood substitutes

Aqueous solutions comprising a polysaccharide oncotic agent, a physiologically compatible buffer, a simple hexose sugar, dissolved chloride salts of calcium, sodium and magnesium, and a dissolved organic salt of sodium are disclosed. The solutions are effective substitutes for blood and may be used to preserve the biological integrity of the organs of a mammalian donor organism as shown by superior anatomical integrity of cryopreserved organs and tissues of subjects perfused with the solution. The solutions may be used for maintaining a partially or substantially completely exsanguinated subject at normal temperatures and at temperatures substantially below those normally maintained by a mammal and may be used in conjunction with hypobaric environments to maintain such partially or completed exsanguinated subjects alive without infusing blood back into the subject.

Plasma-like solution

Methods for using a plasma-like solution

Method of preparing a terminally heat sterilized plasma-like solution

A blood substitute solution and methods for its use are provided. The subject solution contains: subphysiological amounts of potassium ion, 0-10 mM magnesium ion, 70-160 mM sodium ion, 0.5-4.0 mM calcium ion, and 80-170 mM chloride ion; one or more water soluble oncotic agents; an organic carboxylic acid or salt thereof; physiological amounts of a sugar; and a blood clotting factor. The subject solution is further characterized in that it does not include a conventional biological buffer. The subject solutions find use in a variety of different applications, e.g. as blood volume expanders, and the like.

Methods of using plasma expanders and blood substitutes

A microcannula suitable for cannulation of very small blood vessels having a sharp pointed trochar tightly but removable placed in the lumen of the microcannula. The trochar is held in place by contact friction from an area of reduced inside diameter distal to the tip end, formed by welding the end distal of the microcannula to a tube having a slightly larger diameter. A process for making a microcannula is also provided.

Growing community of inventors

Berkeley, CA, United States of America

Harold D Waitz